FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3118524798> ?p ?o ?g. }

• W3118524798 abstract "Abstract Background To assess the effects of proprotein convertase subtilisin/kexin type 9 inhibitor (evolocumab) on lipoprotein particles subfractions with Nuclear Magnetic Resonance spectroscopy in patients with acute coronary syndromes. Methods A total of 99 consecutive patients with ACS were enrolled and assigned to either the experimental group (n = 54) or the control group (n = 45). The combination therapy of PCSK9 inhibitor (Repatha®, 140 mg, q2w) and moderate statin (Rosuvastatin, 10 mg, qn) was administered in the experimental group, with statin monotherapy (Rosuvastatin, 10 mg, qn) in the control group. The therapeutic effects on lipoprotein particle subfractions were assessed with NMR spectroscopy after 8 weeks treatment, and the achievement of LDL-C therapeutic target in both groups were analyzed. Results In the experimental group, after 8 weeks of evolocumab combination treatment, the concentrations of blood lipids (TC, LDL-C and its subfractions [LDL-1 to 6], VLDL-C and its subfractions [VLDL-1 to 5], IDL-C, and HDL-C), lipoprotein particles, and their subfractions [VLDL-P, IDL-P, LDL-P, and its subfractions [LDL-P1 to 6], apoB, and LP(a)] demonstrated therapeutic benefits with statistical significance ( P < 0.05). The decrease in total LDL-P concentrations was mainly due to a decreased concentration of small-sized LDL particles (LDL-P 5 + 6), which was significantly more prominent than the decrease in medium-sized LDL-P (LDL-P3 + 4) and large-sized LDL-P (LDL-P1 + 2) ( P < 0.001). According to lipid control target recommended by the latest China Cholesterol Education Program Expert Consensus in 2019, after 8 weeks treatment, 96.3% patients in the experimental group and 13.3% in the control group had achieved the LDL-C therapeutic target ( P < 0.01). Conclusions Evolocumab combination treatment for 8 weeks significantly improves the plasma lipid profiles in ACS patients, and significantly decrease the concentration of lipoprotein particles which might contribute to the pathonesis of atherosclerosis." @default.
• W3118524798 created "2021-01-18" @default.
• W3118524798 creator A5021504751 @default.
• W3118524798 creator A5061396145 @default.
• W3118524798 creator A5091207179 @default.
• W3118524798 date "2021-01-07" @default.
• W3118524798 modified "2023-10-14" @default.
• W3118524798 title "Effect of PCSK9 inhibitor on lipoprotein particles in patients with acute coronary syndromes" @default.
• W3118524798 cites W1520609538 @default.
• W3118524798 cites W1521001240 @default.
• W3118524798 cites W161816689 @default.
• W3118524798 cites W1891823817 @default.
• W3118524798 cites W1972661406 @default.
• W3118524798 cites W1984875752 @default.
• W3118524798 cites W2012344261 @default.
• W3118524798 cites W2019071303 @default.
• W3118524798 cites W2037968881 @default.
• W3118524798 cites W2069637401 @default.
• W3118524798 cites W2072849188 @default.
• W3118524798 cites W2101702589 @default.
• W3118524798 cites W2106051125 @default.
• W3118524798 cites W2107443630 @default.
• W3118524798 cites W2113438133 @default.
• W3118524798 cites W2123027967 @default.
• W3118524798 cites W2152086330 @default.
• W3118524798 cites W2152354184 @default.
• W3118524798 cites W2155259933 @default.
• W3118524798 cites W2177788247 @default.
• W3118524798 cites W2227482939 @default.
• W3118524798 cites W2554832534 @default.
• W3118524798 cites W2596179513 @default.
• W3118524798 cites W2767900220 @default.
• W3118524798 cites W2800713945 @default.
• W3118524798 cites W2890426109 @default.
• W3118524798 cites W2899997727 @default.
• W3118524798 cites W2902280638 @default.
• W3118524798 cites W2903389211 @default.
• W3118524798 cites W4238580056 @default.
• W3118524798 doi "https://doi.org/10.1186/s12872-020-01827-0" @default.
• W3118524798 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7789487" @default.
• W3118524798 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33413096" @default.
• W3118524798 hasPublicationYear "2021" @default.
• W3118524798 type Work @default.
• W3118524798 sameAs 3118524798 @default.
• W3118524798 citedByCount "8" @default.
• W3118524798 countsByYear W31185247982021 @default.
• W3118524798 countsByYear W31185247982022 @default.
• W3118524798 countsByYear W31185247982023 @default.
• W3118524798 crossrefType "journal-article" @default.
• W3118524798 hasAuthorship W3118524798A5021504751 @default.
• W3118524798 hasAuthorship W3118524798A5061396145 @default.
• W3118524798 hasAuthorship W3118524798A5091207179 @default.
• W3118524798 hasBestOaLocation W31185247981 @default.
• W3118524798 hasConcept C126322002 @default.
• W3118524798 hasConcept C134018914 @default.
• W3118524798 hasConcept C2776839432 @default.
• W3118524798 hasConcept C2778114629 @default.
• W3118524798 hasConcept C2778163477 @default.
• W3118524798 hasConcept C2778849439 @default.
• W3118524798 hasConcept C2780072125 @default.
• W3118524798 hasConcept C2780499067 @default.
• W3118524798 hasConcept C2780745583 @default.
• W3118524798 hasConcept C2780902209 @default.
• W3118524798 hasConcept C2780948078 @default.
• W3118524798 hasConcept C2911022245 @default.
• W3118524798 hasConcept C43554185 @default.
• W3118524798 hasConcept C62746215 @default.
• W3118524798 hasConcept C71924100 @default.
• W3118524798 hasConcept C8004288 @default.
• W3118524798 hasConcept C8243546 @default.
• W3118524798 hasConcept C98274493 @default.
• W3118524798 hasConceptScore W3118524798C126322002 @default.
• W3118524798 hasConceptScore W3118524798C134018914 @default.
• W3118524798 hasConceptScore W3118524798C2776839432 @default.
• W3118524798 hasConceptScore W3118524798C2778114629 @default.
• W3118524798 hasConceptScore W3118524798C2778163477 @default.
• W3118524798 hasConceptScore W3118524798C2778849439 @default.
• W3118524798 hasConceptScore W3118524798C2780072125 @default.
• W3118524798 hasConceptScore W3118524798C2780499067 @default.
• W3118524798 hasConceptScore W3118524798C2780745583 @default.
• W3118524798 hasConceptScore W3118524798C2780902209 @default.
• W3118524798 hasConceptScore W3118524798C2780948078 @default.
• W3118524798 hasConceptScore W3118524798C2911022245 @default.
• W3118524798 hasConceptScore W3118524798C43554185 @default.
• W3118524798 hasConceptScore W3118524798C62746215 @default.
• W3118524798 hasConceptScore W3118524798C71924100 @default.
• W3118524798 hasConceptScore W3118524798C8004288 @default.
• W3118524798 hasConceptScore W3118524798C8243546 @default.
• W3118524798 hasConceptScore W3118524798C98274493 @default.
• W3118524798 hasIssue "1" @default.
• W3118524798 hasLocation W31185247981 @default.
• W3118524798 hasLocation W31185247982 @default.
• W3118524798 hasLocation W31185247983 @default.
• W3118524798 hasLocation W31185247984 @default.
• W3118524798 hasLocation W31185247985 @default.
• W3118524798 hasOpenAccess W3118524798 @default.
• W3118524798 hasPrimaryLocation W31185247981 @default.
• W3118524798 hasRelatedWork W2162657286 @default.
• W3118524798 hasRelatedWork W2344543776 @default.
• W3118524798 hasRelatedWork W2401226202 @default.

• next